[HTML][HTML] PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics

HZ Ying, Q Chen, WY Zhang… - Molecular …, 2017 - … .spandidos-publications.com
The platelet‑derived growth factor (PDFG) signaling pathway exerts persistent activation in
response to a variety of stimuli and facilitates the progression of hepatic fibrosis. Since this …

Mechanistic insights into the pharmacological significance of silymarin

K Wadhwa, R Pahwa, M Kumar, S Kumar, PC Sharma… - Molecules, 2022 - mdpi.com
Medicinal plants are considered the reservoir of diverse therapeutic agents and have been
traditionally employed worldwide to heal various ailments for several decades. Silymarin is a …

Antiviral activities of silymarin and derivatives

CH Liu, A Jassey, HY Hsu, LT Lin - Molecules, 2019 - mdpi.com
Silymarin flavonolignans are well-known agents that typically possess antioxidative, anti-
inflammatory, and hepatoprotective functions. Recent studies have also documented the …

Гепатопротекторы

СВ Оковитый, ВА Приходько, НН Безбородкина… - 2022 - elibrary.ru
В настоящем издании проанализированы и систематизированы сведения по
клиническому применению лекарственных средств, для которых гепатотропное …

Protective role of flavonoids quercetin and silymarin in the viral-associated inflammatory bowel disease: An updated review

E Zarenezhad, HT Abdulabbas, AS Kareem… - Archives of …, 2023 - Springer
Inflammatory bowel disease (IBD) is a chronic recurrent inflammation of the gastrointestinal
tract (GIT). IBD patients are susceptible to various infections such as viral infections due to …

Silibinin and SARS-CoV-2: dual targeting of host cytokine storm and virus replication machinery for clinical management of COVID-19 patients

J Bosch-Barrera, B Martin-Castillo, M Buxó… - Journal of clinical …, 2020 - mdpi.com
COVID-19, the illness caused by infection with the novel coronavirus SARS-CoV-2, is a
rapidly spreading global pandemic in urgent need of effective treatments. Here we present a …

[HTML][HTML] Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases

HA Lee, Y Chang, PS Sung, EL Yoon… - Clinical and …, 2022 - ncbi.nlm.nih.gov
The global burden of chronic liver disease (CLD) is substantial. Due to the limited indication
of and accessibility to antiviral therapy in viral hepatitis and lack of effective pharmacological …

[HTML][HTML] Hepatocellular carcinoma and the risk of occupational exposure

V Rapisarda, C Loreto, M Malaguarnera… - World journal of …, 2016 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the most common type of liver cancer. The main risk
factors for HCC are alcoholism, hepatitis B virus, hepatitis C virus, nonalcoholic …

Silybin: A Review of Its Targeted and Novel Agents for Treating Liver Diseases Based on Pathogenesis

J Wu, L Wen, X Liu, Q Li, Z Sun, C Liang… - Phytotherapy …, 2024 - Wiley Online Library
Liver disease represents a significant global public health concern. Silybin, derived from
Silybum marianum, has been demonstrated to exhibit a range of beneficial properties …

Liver fibrosis: the 2017 state of art

G Caviglia, C Rosso, S Fagoonee, GM Saracco… - Panminerva …, 2017 - iris.unito.it
Liver fibrosis is a wound-healing response to a wide spectrum of chronic liver injuries. It is
characterized by loss of hepatocytes and alteration in hepatic architecture following an …